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Introduction {#phy213959-sec-0001}
============

The repulsive guidance molecule (RGM) family consists of three members, *RGMA*,*RGMB*, and *RGMC* (also known as *HFE2* and *HJV*) (Monnier et al. [2002](#phy213959-bib-0038){ref-type="ref"}; Kuninger et al. [2004](#phy213959-bib-0026){ref-type="ref"}; Niederkofler et al. [2004](#phy213959-bib-0042){ref-type="ref"}; Papanikolaou et al. [2004](#phy213959-bib-0044){ref-type="ref"}; Samad et al. [2004](#phy213959-bib-0051){ref-type="ref"}; Schmidtmer and Engelkamp [2004](#phy213959-bib-0053){ref-type="ref"}), that are encoded by single‐copy genes in human and other vertebrate genomes (Severyn et al. [2009](#phy213959-bib-0054){ref-type="ref"}). The family received its name from a then‐novel axonal guidance molecule termed RGM that was characterized in 2002 (Monnier et al. [2002](#phy213959-bib-0038){ref-type="ref"}). Subsequent studies identified two related proteins in mammals, termed RGMB and RGMC (Papanikolaou et al. [2004](#phy213959-bib-0044){ref-type="ref"}; Samad et al. [2004](#phy213959-bib-0051){ref-type="ref"}; Schmidtmer and Engelkamp [2004](#phy213959-bib-0053){ref-type="ref"}), and fourth member in teleosts, called RGMD (Corradini et al. [2009](#phy213959-bib-0011){ref-type="ref"}; Siebold et al. [2017](#phy213959-bib-0056){ref-type="ref"}). The original RGM is now named RGMA (Corradini et al. [2009](#phy213959-bib-0011){ref-type="ref"}; Severyn et al. [2009](#phy213959-bib-0054){ref-type="ref"}; Siebold et al. [2017](#phy213959-bib-0056){ref-type="ref"}).

RGMA and RGMB have been shown to be expressed in the central nervous system during development (Schmidtmer and Engelkamp [2004](#phy213959-bib-0053){ref-type="ref"}), and their discoveries indicated that they were involved in controlling axonal patterning and neuronal survival (Monnier et al. [2002](#phy213959-bib-0038){ref-type="ref"}; Matsunaga et al. [2004](#phy213959-bib-0035){ref-type="ref"}; Niederkofler et al. [2004](#phy213959-bib-0042){ref-type="ref"}; Rajagopalan et al. [2004](#phy213959-bib-0047){ref-type="ref"}; Samad et al. [2004](#phy213959-bib-0051){ref-type="ref"}). In contrast, RGMC was initially characterized through its gene, which was found within a locus that was linked to a severe form of an iron storage disease that primarily affects children, termed juvenile hemochromatosis (Papanikolaou et al. [2004](#phy213959-bib-0044){ref-type="ref"}). The gene was termed *HFE2* after *HFE* (high iron \[chemical symbol Fe\]), the initial gene whose mutations were found in hemochromatosis (Papanikolaou et al. [2004](#phy213959-bib-0044){ref-type="ref"}). The encoded protein, RGMC, is also called hemojuvelin (HJV), because of its relationship with juvenile hemochromatosis (Papanikolaou et al. [2004](#phy213959-bib-0044){ref-type="ref"}). Unlike RGMA and RGMB, RGMC/HFE2/HJV is produced in the liver and in cardiac and skeletal muscle, and not within the nervous system (Kuninger et al. [2004](#phy213959-bib-0026){ref-type="ref"}; Papanikolaou et al. [2004](#phy213959-bib-0044){ref-type="ref"}; Schmidtmer and Engelkamp [2004](#phy213959-bib-0053){ref-type="ref"}).

RGMA, RGMB, and RGMC are glycosylphosphatidylinositol (GPI) ‐linked cell membrane‐associated glycoproteins (Corradini et al. [2009](#phy213959-bib-0011){ref-type="ref"}; Severyn et al. [2009](#phy213959-bib-0054){ref-type="ref"}; Siebold et al. [2017](#phy213959-bib-0056){ref-type="ref"}), and the paralogs share \~50% amino acid identity and several structural motifs, including 14 cysteine residues in comparable locations within the three proteins (Corradini et al. [2009](#phy213959-bib-0011){ref-type="ref"}; Severyn et al. [2009](#phy213959-bib-0054){ref-type="ref"}; Siebold et al. [2017](#phy213959-bib-0056){ref-type="ref"}). All three RGMs also appear to undergo a series of similar biosynthetic and processing steps leading to both cell‐associated and soluble protein species (Babitt et al. [2005](#phy213959-bib-0002){ref-type="ref"}; Samad et al. [2005](#phy213959-bib-0052){ref-type="ref"}; Kuninger et al. [2006](#phy213959-bib-0027){ref-type="ref"}). All three proteins also interact with members of the bone morphogenetic protein (BMP) family, where they function as co‐receptors (Core et al. [2014](#phy213959-bib-0010){ref-type="ref"}). BMPs are members of the transforming growth factor‐*β* (TGF‐*β*) super‐family, and play key roles in different developmental and cell fate decisions (Hata and Chen [2016](#phy213959-bib-0017){ref-type="ref"}; Morikawa et al. [2016](#phy213959-bib-0039){ref-type="ref"}; Siebold et al. [2017](#phy213959-bib-0056){ref-type="ref"}). BMPs bind as dimers to specific type I and type II serine/threonine kinase receptors, and initiate a protein kinase cascade which culminates in the activation by serine phosphorylation of Smads 1, 5, and 8, signal transducers and transcription factors that regulate the expression of many BMP‐dependent target genes (Hata and Chen [2016](#phy213959-bib-0017){ref-type="ref"}; Morikawa et al. [2016](#phy213959-bib-0039){ref-type="ref"}).

RGM proteins also bind to the cell surface trans‐membrane molecule, neogenin (Matsunaga et al. [2004](#phy213959-bib-0035){ref-type="ref"}, [2006](#phy213959-bib-0036){ref-type="ref"}; Rajagopalan et al. [2004](#phy213959-bib-0047){ref-type="ref"}; Kuns‐Hashimoto et al. [2008](#phy213959-bib-0029){ref-type="ref"}; Yang et al. [2008](#phy213959-bib-0064){ref-type="ref"}), a member of the netrin‐binding, deleted in colon cancer family, which also includes DCC and UNC5 (Keino‐Masu et al. [1996](#phy213959-bib-0024){ref-type="ref"}; Leonardo et al. [1997](#phy213959-bib-0033){ref-type="ref"}; Mehlen and Mazelin [2003](#phy213959-bib-0037){ref-type="ref"}; Bernet and Mehlen [2007](#phy213959-bib-0006){ref-type="ref"}). The actions of RGMA in both neuronal guidance and neuronal survival are mediated by neogenin (Matsunaga et al. [2004](#phy213959-bib-0035){ref-type="ref"}; Conrad et al. [2007](#phy213959-bib-0009){ref-type="ref"}). The other RGM proteins also can bind to neogenin, but it does not appear to play the predominant role in their biological actions (Kuns‐Hashimoto et al. [2008](#phy213959-bib-0029){ref-type="ref"}; Xia et al. [2008](#phy213959-bib-0063){ref-type="ref"}; Yang et al. [2008](#phy213959-bib-0064){ref-type="ref"}; Corradini et al. [2009](#phy213959-bib-0011){ref-type="ref"}; Siebold et al. [2017](#phy213959-bib-0056){ref-type="ref"}).

Major recent advances in human genetics and genomics now present distinct opportunities for improving our knowledge of human physiology and disease susceptibility, and for gaining new insights into human variation, human origins, and evolution (Acuna‐Hidalgo et al. [2016](#phy213959-bib-0001){ref-type="ref"}; Katsanis [2016](#phy213959-bib-0023){ref-type="ref"}; Quintana‐Murci [2016](#phy213959-bib-0046){ref-type="ref"}; Battle et al. [2017](#phy213959-bib-0005){ref-type="ref"}; eGTEx Project, [2017](#phy213959-bib-0016){ref-type="ref"}). Here I use the RGM family to show how to understand and integrate this information, by accessing publically available genomic and gene expression repositories to examine human *RGM* genes in detail. Results reveal extensive variation in gene expression patterns, substantial alternative RNA splicing, and a range of possible missense alterations and other modifications in the coding regions of each of the three genes. Taken together, these observations will provide new opportunities to define the dynamics and range of RGM actions in different physiological and pathological contexts, and will serve as a template and guide that can be applied to other gene families in humans and other species.

Methods {#phy213959-sec-0002}
=======

Databases and analyses {#phy213959-sec-0003}
----------------------

Information on human *RGMA*,*RGMB*, and *RGMC* (*HFE2*/*HJV*) loci and genes was obtained from the Ensembl ([www.ensemble.org](http://www.ensemble.org)) and UCSC Genome Browsers (<https://genome.ucsc.edu>), by searching genome assembly, GRCh38, with each gene name. The different classes of transcripts for each gene were also derived from the Ensembl and UCSC browsers. Data on levels of *RGMA*,*RGMB*, and *RGMC* mRNAs in human tissues were extracted from the Genotype‐Tissue Expression project (GTEx) portal (Battle et al. [2017](#phy213959-bib-0005){ref-type="ref"}) (<https://www.gtexportal.org/>) by searching the "transcriptome" menu with the name of each gene. Relative levels of specific mRNA isoforms were calculated from primary information within the "exon expression" sub‐menu of GTEx. Human RGMA, RGMB, and RGMC protein sequences were isolated from the National Center for Biotechnology Information (NCBI) Consensus CDS Protein Set (<https://www.ncbi.nlm.nih.gov/CCDS/>). Information on predicted population variation in these three proteins was obtained from the Exome Aggregation Consortium (ExAc) genome browser (<http://exac.broadinstitute.org/>), by examining the primary data from each gene after it was downloaded as a series of CSV files. ExAc contains results of sequencing the exons of 60,706 individuals (Karczewski et al. [2017](#phy213959-bib-0022){ref-type="ref"}). Data on predicted alterations in RGMA, RGMB, and RGMC proteins in different cancers were extracted from the cBio portal for Cancer Genomics (<http://www.cbioportal.org/>), which lists gene alterations from 65,690 different individuals from 225 cancer studies (Cerami et al. [2012](#phy213959-bib-0007){ref-type="ref"}; Gao et al. [2013](#phy213959-bib-0014){ref-type="ref"}), and from the National Cancer Institute Genomic Data Commons data portal (<https://portal.gdc.cancer.gov/>), which contains analogous information on 32,555 cancer cases.

Results {#phy213959-sec-0004}
=======

Topography of human RGM loci {#phy213959-sec-0005}
----------------------------

The three single‐copy human *RGM* genes reside on different autosomes. Three other genes are found within the 300 kb segment of chromosome 15q26.1 containing *RGMA* (Fig. [1](#phy213959-fig-0001){ref-type="fig"}A), and the locus is conserved with both mouse and chicken genomes (Severyn et al. [2009](#phy213959-bib-0054){ref-type="ref"}). *RGMB* on human chromosome 5q15 is also a part of a chromosomal region with conserved synteny with mouse and chicken genomes (Severyn et al. [2009](#phy213959-bib-0054){ref-type="ref"}), but only two genes, *CHD1* and *DDX18P4*, are found within the 300 kb region depicted in Figure [1](#phy213959-fig-0001){ref-type="fig"}B. Of note, the paralogous relationship between adjacent genes on both chromosomes, *CHD2* and *RGMA* on chromosome 15 and *CHD1* and *RGMB* on chromosome 5, and their shared convergent transcriptional orientation indicates that these loci were generated by segmental duplication (Severyn et al. [2009](#phy213959-bib-0054){ref-type="ref"}). By contrast with the chromosomal regions of *RGMA* or *RGMB*, the *RGMC/HFE2/HJV* locus on human chromosome 1q21.1 is far more gene dense (Fig. [1](#phy213959-fig-0001){ref-type="fig"}C), and contains nine other genes that also are present in the orthologous mouse locus (Severyn et al. [2009](#phy213959-bib-0054){ref-type="ref"}).

![Organization of human *RGM* loci. (A) Map showing the human *RGMA* locus on chromosome 15q26.1. Genes include *long intergenic non‐protein coding RNA 1578* (*LINC01578*), *clone‐based (Ensembl) gene AC012294.1*,*chromo‐domain helicase DNA binding protein 2* (*CHD2*), and *RGMA*. (B) Illustration of the human *RGMB* locus on chromosome 5q15. Genes include *chromo‐domain helicase DNA binding protein 1* (*CHD1*), *RGMA*, and *DEAD‐box helicase 18 pseudogene 4* (*DDX18P4*). (C) Map showing the human *RGMC*/*HFE2/HJV* locus on chromosome 1q21.1. Genes include the following: ankryin repeat domain 35 (*ANKRD35*), integrin subunit alpha 10 (*ITGA10*), peroxisomal biogenesis factor 11 beta (*PEX11B*), RNA binding motif protein 8A (*RBM8A*), limb and CNS expressed 1 like (*LIX1L*), ankryin repeat domain 34A (*ANKRD34A*), RNA polymerase III subunit G like (*POLR3GL*), thioredoxin interacting protein (*TXNIP*), *RGMC*/*HFE2/HJV*,NBPF member 10 (*NBPF10*). For A--C, the scale bar represents 20 kb, and a horizontal arrow indicates the direction of transcription for each gene.](PHY2-7-e13959-g001){#phy213959-fig-0001}

RGM gene structures and expression patterns in human tissues {#phy213959-sec-0006}
------------------------------------------------------------

The human *RGMA* gene spans \~45 kb of chromosomal DNA and consists of seven exons that are used in the vast majority of transcripts reported within the human Genotype‐Tissue Expression project (GTEx) (Battle et al. [2017](#phy213959-bib-0005){ref-type="ref"}; eGTEx Project, [2017](#phy213959-bib-0016){ref-type="ref"}) (Fig. [2](#phy213959-fig-0002){ref-type="fig"}). The five predominant *RGMA* mRNA isoforms described in GTEx consist of either 3 or 4 exons, and encode one of three very similar RGMA proteins of 434, 450, or 458 amino acids, with all differences being located at the NH~2~‐termini of the proteins (Fig. [2](#phy213959-fig-0002){ref-type="fig"}B). *RGMA* mRNAs are expressed in 48 of the 51 different human organs and tissues found in the GTEx portal. The 10 organs and tissues with the highest abundance of *RGMA* mRNAs include esophagus, colon, skeletal muscle, uterus, tibial nerve, testes, ovary, several brain regions, and adipose tissue (range of expression from 139 to 32 transcripts per kilobase million reads in order (TPM; Fig. [2](#phy213959-fig-0002){ref-type="fig"}C). By contrast, glyceraldehyde 3‐phosphate dehydrogenase (GAPDH), a typical "control" transcript in gene expression studies was 10--70‐times more abundant than RGMA in the organs and tissues examined here (Fig. [2](#phy213959-fig-0002){ref-type="fig"}C). The vast majority of *RGMA* mRNAs found in human tissues according GTEx comprised of isoforms 1 or 2 (\~93--99% of all transcripts; Fig. [2](#phy213959-fig-0002){ref-type="fig"}D). In contrast, the major RGMA protein in the Exome Aggregation Consortium (ExAC) gene dataset is predicted to have 458 amino acids, which is encoded by isoform 5 in Figure [2](#phy213959-fig-0002){ref-type="fig"}B. This mRNA is expressed minimally in the ten human tissues catalogued by GTEx and presented here (Fig. [2](#phy213959-fig-0002){ref-type="fig"}D, and see below).

![Human *RGMA* gene structure and expression. (A) Schematic of the human *RGMA* gene, illustrating exons 1--7, and ATG and TAG codons. Exons are represented as boxes, with coding regions in black and non‐coding segments in white, and introns as horizontal lines. A scale bar is shown. (B) Diagrams of the four major classes of human *RGMA* mRNAs represent the following transcripts from the Ensembl genome browser: isoform 1, ENST00000543599.5; isoform 2, ENST00000329082.11; isoform 3, ENST00000542321.6; and isoform 4, ENST00000425933.6. The protein encoded by each transcript is listed to the right of each diagram. (C) RGMA gene expression in 10 different human tissues and organs. Data were obtained from the GTEx portal, and are graphed as the mean number of transcripts per kilobase million reads (TPM), with the mean transcript abundance of glyceraldehyde 3‐phosphate dehydrogenase (GAPDH) listed to the right of each *RGMA* RNA level. The number of samples for each organ and tissue is as follows: esophagus (370), sigmoid colon (233), skeletal muscle (564), uterus (111), tibial nerve (414), testes (259), ovary (133), substantia nigra (88), cerebral cortex (158) and subcutaneous adipose tissue (42). (D) Relative expression of *RGMA* mRNAs in 10 different human organs and tissues (%) from the GTEx database. Transcripts 1--5 are illustrated in part B above, and mRNAs 6--14 are found in GTEx.](PHY2-7-e13959-g002){#phy213959-fig-0002}

The human *RGMB* gene is slightly more compact than *RGMA*, and its five major exons extend over \~26 kb of genomic DNA (Fig. [3](#phy213959-fig-0003){ref-type="fig"}A). The three predominant transcripts in GTEx also are derived by alternative RNA splicing, but only two of these mRNAs appear to encode RGMB proteins of either 478 or 437 amino acids (Fig. [3](#phy213959-fig-0003){ref-type="fig"}B). *RGMB* transcripts are expressed in 49 of the 51 different organs and tissues found in GTEx; except for esophagus, mRNA levels are 2--3‐fold lower than for *RGMA* mRNAs (compare Figs. [3](#phy213959-fig-0003){ref-type="fig"}C, [2](#phy213959-fig-0002){ref-type="fig"}C). The majority of expressed *RGMB* mRNAs encode RGMB proteins, primarily the 478 amino acid species (isoform 1, Fig. [3](#phy213959-fig-0003){ref-type="fig"}D).

![Human *RGMB* gene structure and expression. (A) Schematic of the human *RGMB* gene, depicting exons 1--5, and ATG and TAG codons. Exons are represented as boxes, with coding regions in black and non‐coding segments in white, and introns as horizontal lines. A scale bar is shown. (B) Diagrams of the three major classes of human *RGMB* mRNAs represent the following transcripts from the Ensembl genome browser: isoform 1, ENST00000308234.11; isoform 2, ENST00000513185.1; and isoform 3, ENST00000434027.2. The protein encoded by each transcript is listed to the right of each diagram. (C) *RGMB* gene expression in 10 different human tissues and organs. Data were obtained from the GTEx portal, and are graphed as TPM. Mean transcript abundance of GAPDH is listed to the right of each *RGMB* RNA level. (D) Relative expression of *RGMB* mRNAs in 10 different human organs and tissues (%) in the GTEx database. Transcripts 1--3 are illustrated in part B above, and mRNAs 4--7 are found in GTEx.](PHY2-7-e13959-g003){#phy213959-fig-0003}

Human *RGMC/HFE2/HJV* at \~4.5 kb in length is substantially smaller than either *RGMA* or *RGMB*, and is composed of four exons and three introns (Fig. [4](#phy213959-fig-0004){ref-type="fig"}A). There are five major transcripts expressed in human organs and tissues, and they encode proteins of variable lengths, from 93 to 426 amino acids (Fig. [4](#phy213959-fig-0004){ref-type="fig"}B). Unlike *RGMA* or *RGMB*,*RGMC/HFE2/HJV* mRNAs can be detected only in human skeletal muscle, liver, and heart, and were found at steady‐state levels that were 9--25‐fold less abundant than GAPDH (Fig. [4](#phy213959-fig-0004){ref-type="fig"}C). Perhaps surprisingly, the *RGMC/HFE2/HJV* mRNA that encodes the full‐length 426‐residue RGMC/HJV protein (isoform 2) comprises only 10--20% of transcripts in human organs and tissues according to GTEx (Fig. [4](#phy213959-fig-0004){ref-type="fig"}D). The reasons for the low level of gene expression for isoform 2 are unknown, but could reflect differential RNA stability, or the technical conditions under which the tissues were obtained and RNA samples isolated and processed (see Discussion).

![Human *RGMC*/*HFE2/HJV* gene structure and expression. (A) Schematic of the human *RGMC*/*HFE2/HJV* gene, illustrating exons 1‐4, and ATG and TAA codons. Exons are depicted as boxes, with coding regions in black and non‐coding segments in white, and introns as horizontal lines. A scale bar is shown. (B) Diagrams of the five major classes of human *RGMC*/*HFE2/HJV* transcripts represent the following mRNAs from the Ensembl genome browser, respectively: isoform 1, ENST00000497365.5; isoform 2, ENST00000357836.5; isoform 3, ENST00000336751.10; isoform 4, ENST00000475797.1; and isoform 5, ENST00000421822.2. The protein encoded by each transcript is listed to the right of each diagram. (C) *RGMC*/*HFE2/HJV* gene expression in different human tissues and organs. Data were obtained from the GTEx portal, and are graphed as TPM. Mean transcript abundance of GAPDH is listed to the right of each *RGMC*/*HFE2/HJV* RNA level. The number of samples for each organ and tissue is as follows: skeletal muscle (564), liver (175), atrial appendage (297), and left ventricle (303). (D) Relative expression of *RGMC*/*HFE2/HJV* mRNAs in different human organs and tissues (%) found in the GTEx database.](PHY2-7-e13959-g004){#phy213959-fig-0004}

Predicted variation in RGM proteins in human populations {#phy213959-sec-0007}
--------------------------------------------------------

ExAC contains DNA sequence information from the exons of genes from 60,706 people representing different population groups from around the world (Bahcall [2016](#phy213959-bib-0003){ref-type="ref"}; Lek et al. [2016](#phy213959-bib-0032){ref-type="ref"}; Ruderfer et al. [2016](#phy213959-bib-0050){ref-type="ref"}; Karczewski et al. [2017](#phy213959-bib-0022){ref-type="ref"}). The data have revealed substantial variation within the coding regions of genes in this large population, but also showed that most alterations were uncommon, as the majority was detected in a single allele, and over 99% were found in \<1% of the study group (Lek et al. [2016](#phy213959-bib-0032){ref-type="ref"}). Most of this previously described variation consists of synonymous nucleotide changes and amino acid substitutions (Lek et al. [2016](#phy213959-bib-0032){ref-type="ref"}).

Examination of RGM family members in ExAC revealed a wide range of potential alterations in their exons, with most of the predicted changes consisting of missense mutations (92--96% of modified alleles, depending on the gene, Table [1](#phy213959-tbl-0001){ref-type="table"}). Second most common were changes in the reading frame, including inserted stop codons (1--7%, Table [1](#phy213959-tbl-0001){ref-type="table"}). Overall, the total number of different allelic variants per gene was similar for all RGM family members, and ranged from 143 for *RGMB* to 185 for *RGMA*, but their population frequency varied by a factor of 60, from 1.4% for *RGMC/HFE2/HJV* to 86% for *RGMA*, with the vast majority of changes being accounted for just a few modifications (Fig. [5](#phy213959-fig-0005){ref-type="fig"}). As 99.1% of missense alleles were detected in ≤1% of the ExAC study population, overall results regarding the frequency of differences in the human RGM family proteins are consistent with the general conclusions from ExAC (Lek et al. [2016](#phy213959-bib-0032){ref-type="ref"}), with the exception of the few highly prevalent allelic variants depicted in Figure [5](#phy213959-fig-0005){ref-type="fig"}.

###### 

Human population variation in RGMA, RGMB, and RGMC

  Protein   Number of codons[1](#phy213959-note-0002){ref-type="fn"}   Missense and in‐frame insertions‐deletions   Frame shifts; stop codons   Splicing site changes   Loss of start codon   Loss of stop codon   Total number of different changes   Variants occurring once   Total variant alleles in population
  --------- ---------------------------------------------------------- -------------------------------------------- --------------------------- ----------------------- --------------------- -------------------- ----------------------------------- ------------------------- -------------------------------------
  RGMA      458                                                        178                                          2                           5                       0                     0                    185                                 96                        86.0%
  RGMB      478                                                        134                                          6                           3                       0                     0                    143                                 78                        9.1%
  RGMC      426                                                        157                                          12                          1                       1                     0                    171                                 109                       1.4%

Based on transcripts used in ExAC database. All RGMB and RGMC variants mapped to the 478 or 426 codons, respectively, corresponding to a full‐length protein. For RGMA, 17 variants were not counted as they mapped to a transcript corresponding to a smaller predicted protein of 61 residues that undergoes rapid decay.
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![Population variation in human RGM proteins. (A--C) The three human RGM protein precursors are composed of four identifiable regions, termed the signal peptide (SP), N‐terminal RGM (N‐RGM domain), C‐terminal RGM (C‐RGM segment), which includes a partial von Willebrand factor type D domain (vWFD), and the glycosylphosphatidylinositol recognition sequence (GPI), which is cleaved as part of the biosynthetic steps leading to glycosylphosphatidylinositol addition to the maturing protein (Lebreton et al. [2018](#phy213959-bib-0031){ref-type="ref"}). The scale bar represents 100 amino acids. The location of the GDPH autocatalytic cleavage site (Siebold et al. [2017](#phy213959-bib-0056){ref-type="ref"}) is listed above each diagram. (A) Human RGMA highlighted by ExAC consists of a 458‐residue protein. The overall population prevalence of variant alleles for each segment of the protein is listed below the map, and the most common variants are illustrated in single letter amino acid code. (B) The human RGMB found in ExAC consists of 478‐amino acids. The population prevalence of variant alleles for each segment of the protein is listed below the map, and the most common variants are depicted in single letter amino acid code. (C) Human RGMC/HJV consists of a 426‐residue protein in ExAC. The overall population prevalence of variant alleles for each segment of the protein is listed below the map, and the most common variants are shown in single letter amino acid code.](PHY2-7-e13959-g005){#phy213959-fig-0005}

Population variation in RGMA {#phy213959-sec-0008}
----------------------------

Alterations in *RGMA* have not been linked to date with the pathogenesis of any specific human diseases. Thus, the functional consequences of three prevalent specific amino acid substitutions in the RGMA protein (Leu^4^ to Pro in the signal peptide (8.5% in the population), the conservative substitution of Asp^423^ to Glu in the C‐terminal RGM domain (63.1%), and Ala^439^ to Val in the GPI‐anchor segment (11.9%), Fig. [5](#phy213959-fig-0005){ref-type="fig"}A) in either human physiology or pathology are not known.

As with some other proteins, a large number of alterations in *RGMA* have been found to be associated with a variety of different cancers, according to the analysis of data in the cBio portal for Cancer Genomics (Table [2](#phy213959-tbl-0002){ref-type="table"}) and the National Cancer Institute Genomic Data Commons portal, although the functional consequences are unknown. Potential mutations at 78 different locations in *RGMA* coding exons have been detected in 38 different neoplasms, with the prevalence of these changes ranging from 3.5% in ovarian cancer and 2.8% in esophageal, gastric, and small cell lung cancer, and in soft tissue sarcoma, to \<0.3% in prostate and renal carcinoma, various leukemias and lymphomas, and others (see cancer type in: <http://www.cbioportal.org/index.do?session_id=5b5f49be498eb8b3d5672991>). The vast majority of alterations consisted of amino acid substitutions (76 different modifications at 71 different sites; Table [2](#phy213959-tbl-0002){ref-type="table"}), of which 43 at 32 locations were present in the ExAC population, although generally at low frequency (Table [2](#phy213959-tbl-0002){ref-type="table"}). However, three of the cancer‐associated amino acid substitutions were among the more common allelic variants in the population (Leu^4^ to Pro, 8.5% of ExAC alleles, Ala^439^ to Val, 11.9%, and Arg^441^ to Trp, 0.6%; Fig. [5](#phy213959-fig-0005){ref-type="fig"}A), and thus may have been detected by chance rather than through disease association. However, the most prevalent allele in ExAC, Asp^423^ to Glu, seen in 63.1% of the population (Fig. [5](#phy213959-fig-0005){ref-type="fig"}A), was absent in any of the cancer studies compiled here (Table [2](#phy213959-tbl-0002){ref-type="table"}). Other changes associated with different neoplasms included premature stop codons and frame‐shifts, none of which were found in ExAC (seven examples, Table [2](#phy213959-tbl-0002){ref-type="table"}).

###### 

Cancer‐associated mutations in RGMA[1](#phy213959-note-0003){ref-type="fn"}

  Mutation                                             Population variant   ExAC prevalence
  ---------------------------------------------------- -------------------- ------------------
  L4P                                                  L4P                  10396 alleles
  L16V                                                 None                 --
  R21P                                                 None                 --
  M27I                                                 None                 --
  G30E                                                 None                 --
  S34stop                                              None                 --
  F38L                                                 F38S                 1 allele
  P40S                                                 None                 --
  A43D                                                 A43V                 1 allele
  F44L                                                 F44C                 3 alleles
  P55L                                                 P55L                 15 alleles
  G71C                                                 None                 --
  D79G                                                 D79N, D79Y           1, 1 allele
  P81L                                                 None                 --
  R88H                                                 R88H                 1 allele
  R95L, R95Q, R95W                                     R95Q                 7 alleles
  R96W                                                 R96Q, R96W           3, 6 alleles
  T97M                                                 None                 --
  D104N                                                None                 --
  H108N                                                None                 --
  S119T                                                None                 --
  R133C                                                R133G, R133H         5, 8 alleles
  R135H                                                R135C, R135H         4, 5 alleles
  P139L                                                P239S, P139T         21, 143 alleles
  E145Q                                                None                 --
  E151K                                                E151K                1 allele
  E156K                                                None                 --
  P164S                                                None                 --
  H170Tfs34stop                                        None                 --
  G175R                                                G175R                1 allele
  T181I                                                None                 --
  T189I                                                None                 --
  P196L                                                None                 --
  N204S                                                N204K                1 allele
  P211H                                                None                 --
  A217V                                                A217V                3 alleles
  Q231R                                                None                 --
  E233A, E233K                                         None                 --
  P248S                                                P248L                1 allele
  V252L                                                V252M                5 alleles
  K256stop                                             None                 --
  S266N                                                None                 --
  E271K, E271stop                                      None                 --
  A281D                                                None                 --
  V290M                                                None                 --
  R292C                                                None                 --
  V302A, V302I                                         V302I                13 alleles
  M304I                                                None                 --
  V309A                                                None                 --
  E313K                                                None                 --
  W315L                                                W315G                1 allele
  R325W                                                R325Q, R325W         1, 4 alleles
  G326V                                                None                 --
  G346S                                                G346S                1 allele
  R348H                                                R348C, R348H         15, 42 alleles
  L350M                                                None                 --
  A353T                                                A353T                2 alleles
  P357S                                                None                 --
  E3613Rfs36[1](#phy213959-note-0003){ref-type="fn"}   None                 --
  V369M                                                V369L, V369M         6, 1 alleles
  C372stop                                             C372R, C372Y         1, 1 alleles
  V378A                                                V378M                1 allele
  E379stop                                             None                 --
  V387I                                                None                 --
  D389N                                                None                 --
  D395N                                                None                 --
  V396M                                                None                 --
  A402T                                                None                 --
  V404M                                                None                 --
  A405V                                                None                 --
  L406F                                                None                 --
  L412I                                                None                 --
  P429L                                                None                 --
  A432V                                                A432V                4 alleles
  A439V                                                A439G, A439G         1, 14451 alleles
  R441T                                                R441Q, R441W         34, 668 alleles
  P442A                                                P442L                1 allele
  A446T                                                A446P, A446T         1, 7 alleles

Amino acid positions modified to agree with ExAC assignments (see Text).
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Population variation in RGMB {#phy213959-sec-0009}
----------------------------

Changes in *RGMB* also have not been connected to the pathogenesis of any human diseases to date. As with *RGMA*, the functional consequences to human physiology or pathology of the single predicted single amino acid substitution in *RGMB* that is prevalent in the ExAC population (Ser^63^ to Arg in the signal peptide (7.8%), Fig. [5](#phy213959-fig-0005){ref-type="fig"}B) are unknown.

Changes in *RGMB* also have been detected in a number of different cancers (Table [3](#phy213959-tbl-0003){ref-type="table"}), but as with *RGMA*, the possible functional impacts are not known. Potential mutations have been identified at 69 different locations in coding portions of the *RGMB* gene in 38 cancer studies, with the prevalence of these changes ranging from nearly 10% in prostate cancer and 7.5% in adrenocortical carcinoma to 0.3% or less in cervical, thyroid, bone, skin, and brain cancers, in leukemias and lymphomas, and in other neoplasms (see cancer type in: <http://www.cbioportal.org/index.do?session_id=5b609381498eb8b3d5672df4>). Most of the alterations consisted of amino acid substitutions (73 different modifications; Table [3](#phy213959-tbl-0003){ref-type="table"}), of which 26 at 19 sites were identified in ExAC at a frequency of 0.1--0.001% (Table [3](#phy213959-tbl-0003){ref-type="table"}), except for the highly prevalent Ser^63^ to Arg allele at 7.8% (Fig. [5](#phy213959-fig-0005){ref-type="fig"}B). The other 18 changes, which included both premature stop codons and frame‐shifts, which led to stop codons, were not found in ExAC (Table [3](#phy213959-tbl-0003){ref-type="table"}).

###### 

Cancer‐associated mutations in RGMB[1](#phy213959-note-0004){ref-type="fn"}

  Mutation               Population variant   ExAC prevalence
  ---------------------- -------------------- -----------------
  R49Kfs51stop           None                 --
  S63R                   S63R                 9454 alleles
  Q90stop                None                 --
  A93Nfs14stop           A93T                 1 allele
  Q94H                   None                 --
  R96Q                   R96Q, R96stop        132, 1 alleles
  S104R                  None                 --
  V105E                  None                 --
  H110P                  None                 --
  E120stop               None                 --
  E121Vfs34stop          E121A, E121stop      1, 1 alleles
  R127C                  R127H                2 alleles
  R135Q                  R135Q                1 allele
  C140Y                  None                 --
  R141H                  R141C, R141H         2, 11 alleles
  N143S                  None                 --
  V145L, V145_Y105insL   None                 --
  H147D                  None                 --
  L151F                  None                 --
  L156H                  None                 --
  Q159H                  None                 --
  R160M                  None                 --
  G166stop               None                 --
  H183Qfs35stop          None                 --
  E190Tfs28stop          None                 --
  L206F                  None                 --
  L230I                  None                 --
  N233D                  N233T                1 allele
  N234del                None                 --
  V243I                  V243E, V243I         8, 4 alleles
  P244H                  None                 --
  G248E                  None                 --
  X257_splice                                 
  A263G                  None                 --
  C267Y                  None                 --
  T268K                  None                 --
  Y273stop               None                 --
  A283T                  A283T                1 allele
  G287D                  None                 --
  G292R, G292V           None                 --
  R300H                  R300C, R300H         4, 4 alleles
  V302L, V302M           V302M                8 alleles
  G307A                  None                 --
  A314P                  A314T, A314V         1, 2 alleles
  R328C, R328H           R328C                1 allele
  R335C                  None                 --
  A341V                  None                 --
  Q351K                  None                 --
  E361K                  None                 --
  L392Gfs9stop           None                 --
  Q398E                  None                 --
  E401Q                  None                 --
  P404S                  None                 --
  Y409D                  Y409C                1 allele
  F415V                  None                 --
  T420N                  None                 --
  F425L                  None                 --
  A428T                  A428P, A428T         2, 5 alleles
  L433Gfs9stop           None                 --
  E3434stop,             None                 --
  A438V                  None                 --
  K443N                  None                 --
  S451N                  None                 --
  N454Kfs9stop           N454S                3 alleles
  T456I                  None                 --
  R458H                  R458H                4 alleles
  L463stop               L463F                2 alleles
  T470Nfs33stop          None                 --
  L478stop               None                 --

Amino acid positions modified to agree with ExAC assignments (see Text).
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Disease links and population variation in RGMC/HFE2/HJV {#phy213959-sec-0010}
-------------------------------------------------------

Unlike other members of the human RGM family, *RGMC/HFE2/HJV* was first characterized as the gene associated with the severe iron storage disease, juvenile hemochromatosis (Papanikolaou et al. [2004](#phy213959-bib-0044){ref-type="ref"}), and identification of mutations in the gene in affected individuals defined causality (Lanzara et al. [2004](#phy213959-bib-0030){ref-type="ref"}; Papanikolaou et al. [2004](#phy213959-bib-0044){ref-type="ref"}; Gehrke et al. [2005](#phy213959-bib-0015){ref-type="ref"}), which was confirmed by mouse gene knockout models (Huang et al. [2005](#phy213959-bib-0019){ref-type="ref"}; Niederkofler et al. [2005](#phy213959-bib-0043){ref-type="ref"}). The majority of over 40 different mutations that have been found in the individuals with juvenile hemochromatosis are amino acid substitutions, but more than a third predict truncated proteins because of introduced premature stop codons (Table [4](#phy213959-tbl-0004){ref-type="table"}). Almost half of these disease‐associated alleles can be found in the ExAC population, but nearly all are present at very low prevalences of 0.025--0.001% (Table [4](#phy213959-tbl-0004){ref-type="table"}). The only exception, Ala^310^ to Gly, is the most common *RGMC/HFE2/HJV* variant in ExAC, and has a population frequency of 0.7% (Fig. [5](#phy213959-fig-0005){ref-type="fig"}C).

###### 

Juvenile hemochromatosis‐linked mutations in RGMC/HJV

  Mutation          Population variant       ExAC prevalence
  ----------------- ------------------------ -----------------
  Q6H               Q6H                      3 alleles
  L27fs51stop       None                     --
  R54stop           None                     --
  G66stop           None                     --
  V74fs113stop      None                     --
  C80R              C80R                     1 allele
  S85P              None                     --
  G99R, G99V        None                     --
  L101P             L101P                    1 allele
  C119F             None                     --
  R131fs245stop     R131W                    1 allele
  D149fs245stop     None                     --
  L165stop          L165stop                 1 allele
  A168D             A168V                    1 allele
  F170S             None                     --
  D172E             D172E                    1 allele
  R176C             None                     --
  W191C             None                     --
  L194P             L194P                    1 allele
  N196K             None                     --
  S205R             None                     --
  I222N             I222M, I222N             1, 1 alleles
  K234stop          None                     --
  D249H             None                     --
  G250V             None                     --
  N269fs311stop     N269S                    1 allele
  I281T             None                     --
  R288W, R288Y      R288Q, R288W             1, 2 alleles
  E302K             E302D, E302K             1, 32 alleles
  A310G             A310G                    846 alleles
  Q312stop          None                     --
  G319fs341stop     G319A                    3 alleles
  G320V             G320V, G320W             21, 2 alleles
  C321W, C321stop   C321W, C321Y, C321stop   2, 1, 1 alleles
  R326stop          R326Q, R326stop          5, 2 alleles
  S328fs337stop     S328T                    1 allele
  R335Q             R335Q, R335W             9, 1 alleles
  C361fs366stop     None                     --
  N372D             N372D, N372H             1, 1 alleles
  R385stop          R385G, R385Q, R385stop   1, 2, 1 alleles
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Potential alterations in *RGMC/HFE2/HJV* also are present in different cancers, but as with *RGMA* and *RGMB*, the possible functional consequences have not been determined. Predicted mutations (116, Table [5](#phy213959-tbl-0005){ref-type="table"}) have been identified at 102 different codons in 38 different neoplastic diseases, with the prevalence of these alterations ranging from 25% in prostate cancer, 10% in ovarian cancer, and 8.4% in melanoma, to 0.6% or less in colorectal carcinoma, salivary gland and renal cancer, leukemia, lymphomas, and others (see <http://www.cbioportal.org/index.do?session_id=5b60fc90498eb8b3d5672fba>). Putative amino acid substitutions or deletions predominated (106 different modifications at 92 locations; Table [5](#phy213959-tbl-0005){ref-type="table"}). Only 11 of these alterations were present in ExAC, with 9 having allelic frequencies of \<0.002% (Table [5](#phy213959-tbl-0005){ref-type="table"}), and the others, a deletion or a duplication of Gly^69^, at 0.06 or 0.13%, respectively (Table [5](#phy213959-tbl-0005){ref-type="table"}). The other 10 changes consisted of premature stop codons and frame‐shifts, and except for Arg^385^ to stop codon were not found in ExAC (Table [5](#phy213959-tbl-0005){ref-type="table"}).

###### 

Cancer‐associated mutations in RGMC/HJV

  Mutation                              Population variant              ExAC prevalence
  ------------------------------------- ------------------------------- --------------------
  G2V                                   None                            --
  P8L, P8S, P8T                         None                            --
  G15D                                  None                            --
  L20I                                  None                            --
  T22N                                  None                            --
  L25I                                  None                            --
  L27M                                  None                            --
  L28I                                  None                            --
  L29I                                  None                            --
  S35F                                  None                            --
  I39T                                  None                            --
  R41C                                  R41C, R41L                      1, 1 allele
  V47L                                  None                            --
  A61E                                  None                            --
  G67E                                  None                            --
  G69del                                G69del, G69dup                  76, 154 alleles
  Y86S                                  None                            --
  A94T                                  None                            --
  R95H                                  R95G                            1 allele
  D100E, D100N                          D100H                           1 allele
  F103L                                 None                            --
  S105Ffs45stop                         None                            --
  I110V                                 I110M                           1 allele
  D112Y                                 None                            --
  M114I                                 None                            --
  I115L, I115M                          None                            --
  Q116K                                 None                            --
  N118Y                                 N118S                           1 allele
  Q122K                                 None                            --
  P129S                                 P129L                           9 alleles
  P133L                                 None                            --
  P136S                                 None                            --
  G141D                                 None                            --
  A144V                                 A144S, A144T                    1, 1 allele
  E151K                                 None                            --
  G159D                                 G159S                           2 alleles
  R160C, R160H                          None                            --
  F164del                               None                            --
  R176C, R176H                          None                            --
  N196H, N196S                          None                            --
  S206F                                 None                            --
  M208Wfs38stop                         M208V, M208T, M208W             1, 1, 1 allele
  A209V                                 None                            --
  L210S                                 None                            --
  T215I                                 T215A                           1 allele
  R218Q, R218W                          None                            --
  T221S                                 None                            --
  K225N                                 None                            --
  M227T                                 None                            --
  I231V                                 I231T                           2 alleles
  E239Q                                 E239G                           4 alleles
  L243F                                 None                            --
  D249G                                 None                            --
  S251Y                                 None                            --
  G260E, G260R                          None                            --
  S261Ifs9stop                          None                            --
  S262G                                 None                            --
  L263F                                 None                            --
  S264L                                 S264L                           2 alleles
  Q266stop                              None                            --
  N269K                                 N269S                           1 allele
  Y280N, Y280Hfs25stop, Y280Hfs31stop   None                            --
  R288Q                                 R288Q, R288W                    1, 2 alleles
  A305V                                 None                            --
  A307S                                 None                            --
  D313N                                 D313N                           2 alleles
  C317W                                 None                            --
  C321Vfs21stop                         C321Y, C321W, C321stop          1, 2, 1 alleles
  P323L                                 None                            --
  R329Q                                 R329L, R329P, R329Q, R329stop   2, 2, 2, 1 alleles
  S330L                                 None                            --
  E331D                                 E331Q                           1 allele
  R332H                                 R332C, R332H                    1, 5 alleles
  N333K                                 N333S                           1 allele
  R334H                                 R334H                           7 alleles
  T339S                                 T339N                           1 allele
  I340T                                 None                            --
  R345W                                 R345Q, R345W                    3, 1 alleles
  K348N, K348R                          None                            --
  E349K                                 None                            --
  S360F                                 None                            --
  S368Y                                 None                            --
  P371S                                 P371L                           1 allele
  F373C                                 None                            --
  A376E                                 None                            --
  A379T                                 A379E                           1 allele
  R385stop                              R385G, R385Q, R385stop          1, 2, 1 alleles
  L396F                                 None                            --
  P398L, P398S                          None                            --
  D400V                                 None                            --
  A401V                                 None                            --
  G402E                                 None                            --
  V403A                                 V403I                           1 allele
  S406F                                 None                            --
  L415F, L415H                          None                            --
  S416F, S416Y                          S416P                           2 alleles
  L421M                                 None                            --
  W422stop                              W422C                           1 allele
  L423I                                 None                            --
  I425T                                 None                            --
  Q426stop                              None                            --
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Discussion {#phy213959-sec-0011}
==========

Information extracted from publically available databases has been collected and then analyzed here to gain insights into the genomics and population genetics of the RGM family in humans. Results identify extensive variation in gene expression patterns, substantial alternative RNA splicing, and a range of possible missense alterations and other modifications in the coding regions of each of the three genes studied, which were not apparent previously, and in many cases are detected in individuals with different types of cancers (Tables [2](#phy213959-tbl-0002){ref-type="table"}, [3](#phy213959-tbl-0003){ref-type="table"}, [5](#phy213959-tbl-0005){ref-type="table"}). In addition, the data show that selected amino acid substitutions are highly prevalent in the world\'s population, with minor allele frequencies of up to 37% for RGMA and up to 8% for RGMB (Fig. [5](#phy213959-fig-0005){ref-type="fig"}). Collectively, these results indicate that protein sequence variation is common in the human RGM family, as has been observed for some other human proteins (Rotwein [2017a](#phy213959-bib-0048){ref-type="ref"},[b](#phy213959-bib-0049){ref-type="ref"}), and it thus appears likely that these variants could have a significant population impact on human physiology and/or disease predisposition.

RGMA and RGMB: genes, mRNAs, and proteins {#phy213959-sec-0012}
-----------------------------------------

By combining information from the Ensembl and UCSC Genome Browsers with data extracted from GTEx, complex patterns of expression have been elucidated here for each human *RGM* gene, particularly in the distribution of different mRNA isoforms (Figs. [2](#phy213959-fig-0002){ref-type="fig"}, [3](#phy213959-fig-0003){ref-type="fig"}, [4](#phy213959-fig-0004){ref-type="fig"}). For example, these results now demonstrate that both *RGMA* and *RGMB* genes are widely expressed in many different adult human organs and tissues, with most of the transcripts encoding one of the several "full‐length" proteins, as differences among these isoforms are found primarily at the NH~2~‐terminus in the presumptive signal peptides (Figs. [2](#phy213959-fig-0002){ref-type="fig"}, [3](#phy213959-fig-0003){ref-type="fig"}). Although a few studies have examined possible effects of RGMA or RGMB in humans (Demicheva et al. [2015](#phy213959-bib-0013){ref-type="ref"}; Shi et al. [2015](#phy213959-bib-0055){ref-type="ref"}; Li et al. [2016](#phy213959-bib-0034){ref-type="ref"}; Muller et al. [2016](#phy213959-bib-0040){ref-type="ref"}), most publications to date have focused on experimental model systems (Matsunaga et al. [2004](#phy213959-bib-0035){ref-type="ref"}, [2006](#phy213959-bib-0036){ref-type="ref"}; Niederkofler et al. [2004](#phy213959-bib-0042){ref-type="ref"}; Rajagopalan et al. [2004](#phy213959-bib-0047){ref-type="ref"}; Samad et al. [2004](#phy213959-bib-0051){ref-type="ref"}; Hata et al. [2006](#phy213959-bib-0018){ref-type="ref"}; Tanabe and Yamashita [2014](#phy213959-bib-0059){ref-type="ref"}). Thus, these new observations will provide opportunities to develop new insights into *RGMA* and *RGMB* gene regulation and their protein functions in a variety of human physiological and pathological processes. Of particular note here is the fact that according to GTEx both *RGMA* and *RGMB* are expressed at similarly high transcript levels in the muscularis region of the esophagus, and within the gastro‐esophageal junction (Figs. [2](#phy213959-fig-0002){ref-type="fig"}C, [3](#phy213959-fig-0003){ref-type="fig"}C, and not shown), raising the question of whether either or both proteins might be involved in aspects of smooth muscle function, such as its coordination by the sympathetic and parasympathetic nervous systems or other signals during swallowing or digestion of food (Woodland et al. [2013](#phy213959-bib-0062){ref-type="ref"}). As mRNAs encoding neogenin (*NEO1*) and BMP receptors (*BMPR1A*,*BMPR1B*, and *BMPR2*) also are expressed in these parts of the esophagus, it is conceivable that different RGM‐mediated signaling pathways could be active in different parts of this organ.

Another surprising observation with regard to *RGMA* and *RGMB* is their expression in a range of different cancers, with transcripts encoding mutant proteins being detected in up to 10% of cases of prostate cancer (*RGMB*) and in 3.5% of ovarian carcinomas (*RGMA*, see Results), again providing evidence for their unexplored roles in human disease. As the majority of these predicted mutations were found to be rare in the general population used in ExAC (although nearly all of the most highly prevalent amino acid substitution alleles were present; see Tables [2](#phy213959-tbl-0002){ref-type="table"} and [3](#phy213959-tbl-0003){ref-type="table"}), these data argue for possible pathophysiological actions for RGMA and RGMB in human neoplasms, and represent another illustration in which focused analysis of information extracted from large‐scale databases can help identify new areas of investigation with possible biomedical consequences.

The special case of RGMC/HFE2/HJV {#phy213959-sec-0013}
---------------------------------

Data collected and assessed from Ensembl, the UCSC Genome Browser, and GTEx also have revealed some unexpected aspects of human *RGMC/HFE2/HJV* gene expression (Fig. [4](#phy213959-fig-0004){ref-type="fig"}). Even though restriction of transcripts to skeletal muscle, liver, and heart had been recognized previously (Kuninger et al. [2004](#phy213959-bib-0026){ref-type="ref"}; Papanikolaou et al. [2004](#phy213959-bib-0044){ref-type="ref"}; Schmidtmer and Engelkamp [2004](#phy213959-bib-0053){ref-type="ref"}), remarkably it now appears that only \~20% of *RGMC/HFE2/HJV* mRNAs found in human tissues encode the 426‐amino acid full‐length protein (Fig. [4](#phy213959-fig-0004){ref-type="fig"}D). The other mRNAs, which comprise the vast majority of transcripts in each tissue type (80 to 90%, Fig. [4](#phy213959-fig-0004){ref-type="fig"}D), encode proteins that are truncated at the NH~2~‐terminus. These latter species lack most of the N‐RGM domain (313‐residue isoform), all of the N‐RGM segment and the entire von Willebrand factor type D domain (200‐amino acid protein), or all but 93‐amino acids in the center of the molecule (Figs. [4](#phy213959-fig-0004){ref-type="fig"}B, [5](#phy213959-fig-0005){ref-type="fig"}C). The observations also raise questions regarding which of these variant RGMC/HJV proteins are biologically active molecules, and what are their presumptive activities. In animal and cell‐based studies, several different‐length versions of RGMC/HJV have been noted, but these have been characterized as being derived from differential protein processing during biosynthesis, and from proteolytic cleavage of the mature GPI‐linked cell surface molecule either by pro‐protein convertases such as furin (Kuninger et al. [2006](#phy213959-bib-0027){ref-type="ref"}, [2008](#phy213959-bib-0028){ref-type="ref"}; Silvestri et al. [2008a](#phy213959-bib-0057){ref-type="ref"}), or by the serine protease, matriptase‐2 (Silvestri et al. [2008b](#phy213959-bib-0058){ref-type="ref"}). Thus, these new observations, which have resulted from analyses of information in databases, define a potentially novel and alternative way that different RGMC/HJV protein isoforms are produced in humans.

Unlike what is observed for RGMA and RGMB, presumptive RGMC/HJV protein variants within the ExAC population are very uncommon, collectively occurring in \<1.5% of 60,706 genomes versus 86% for RGMA and 9% for RGMB (Fig. [5](#phy213959-fig-0005){ref-type="fig"}). Moreover, even though 17 of 43 amino acid substitution, frame‐shift, and stop codon mutations associated with juvenile hemochromatosis have been found in the ExAC study cohort, only a single disease‐associated allele is present in more than 0.025% of the population (Ala^310^ to Gly, at \~0.7%), and 13 are represented just 1--3 times in the 121,412 ExAC alleles (Table [4](#phy213959-tbl-0004){ref-type="table"}). This result suggests that any possible contribution of *RGMC*/*HFE2/HJV* heterozygosity toward iron overload in the general population is minimal, in marked contrast to the high prevalence of HFE protein variants, at least in European‐derived groups (Barton et al. [2015](#phy213959-bib-0004){ref-type="ref"}; Wallace and Subramaniam [2016](#phy213959-bib-0061){ref-type="ref"}).

As seen for RGMA and RGMB, predicted mutations of RGMC/HJV are found in many different cancers, with transcripts encoding mutant proteins being detected in 25% of prostate cancers, 10% of ovarian carcinomas, and 8.4% of melanomas (see Results). Remarkably, both prostate and ovarian cancers are the diseases in which mutant RGMB and RGMA molecules also have been found at highest prevalence, respectively (see Results and above). Moreover, only \~10% of the 106 different mutations in RGMC/HJV detected in cancers are present in ExAC, with all but one of them being rare (found fewer than 5 times) in the 121,412 alleles studied (Table [5](#phy213959-tbl-0005){ref-type="table"}).

Limitations and strengths of population‐based sequence data for understanding RGM actions {#phy213959-sec-0014}
-----------------------------------------------------------------------------------------

As with any large‐scale DNA or RNA‐based sequencing project, ExAC and GTEx respectively contain the potential materials for new biological and biomedical applications, as well as errors and ambiguities. From the perspective of the three *RGM* family genes, potential problems include the choice of minor transcripts as the reference sequences for proteins. This is especially true for RGMA, in which the mRNA species encoding the 458‐amino acid protein isoform selected by ExAC (see Table [1](#phy213959-tbl-0001){ref-type="table"}) appears to comprise ≤2% of transcripts in human organs and tissues in GTEx (isoform 5, Fig. [2](#phy213959-fig-0002){ref-type="fig"}D). In contrast, for RGMB, the predominant transcript in 9 of the 10 tissues surveyed in GTEx encodes the major 478‐residue protein species (all but testes, Fig. [3](#phy213959-fig-0003){ref-type="fig"}D). Another complication here is the potential variation in RNA quality in GTEx samples, especially since both the time from tissue harvesting to RNA extraction and the methods employed to isolate RNA are unknown. It thus seems possible that transcript degradation may skew the results seen in GTEx RNA‐sequencing libraries derived from at least some of the different organs and tissues. Furthermore, as the population distribution of the GTEx dataset is unknown, there are no data to determine whether or not expression of different mRNA isoforms varies among different groups, perhaps in conjunction with population‐specific DNA polymorphisms (Khera et al. [2018](#phy213959-bib-0025){ref-type="ref"}; Yengo et al. [2018](#phy213959-bib-0065){ref-type="ref"}). Other limitations that could contribute to problems in data interpretation include the potential non‐representative nature of the ExAC study population, as over 60% of samples are derived from European individuals, with \~20% from South or East Asians, and only \~8% each from Hispanic or African groups (Lek et al. [2016](#phy213959-bib-0032){ref-type="ref"}). Thus, the actual rate and potential extent of variation among RGM proteins has not been established fully yet, and could change once exome sequencing data are obtained from more individuals and are expanded to include larger numbers of people from different human population groups. Moreover, there is an undefined but probable error rate associated with nucleotide changes that appear only once or just a few times in the 121,412 ExAC chromosomes studied.

Despite these challenges and difficulties, the data in ExAC, GTEx, and in the various cancer medicine portals examined here, provide potentially exciting new opportunities to evaluate contributes of the RGM family, and RGMA and RGMB in particular, to human physiology and disease. Since *RGMA* and *RGMB* are expressed in the vast majority of adult human organs and tissues (48 of 51 for *RGMA* and 49 of 51 for *RGMB*), the encoded proteins are likely to be involved in some regulatory processes. Perhaps immune cell function is in one of these areas, since RGMA is expressed in dendritic cells and neogenin is found in CD4 +  T lymphocytes (Muramatsu et al. [2011](#phy213959-bib-0041){ref-type="ref"}).

Modern human populations represent the outcomes of many interactions over long time frames with different ancestral groups. Not only do the DNA marks in our genomes derived from extinct populations such as Neanderthals, Denisovans, and others document these past relationships (Jones et al. [2015](#phy213959-bib-0021){ref-type="ref"}; Vattathil and Akey [2015](#phy213959-bib-0060){ref-type="ref"}; Clarkson et al. [2017](#phy213959-bib-0008){ref-type="ref"}; Hublin et al. [2017](#phy213959-bib-0020){ref-type="ref"}), but some of the introgressed DNA continues to influence human physiology or disease susceptibility to the present day (Dannemann and Kelso [2017](#phy213959-bib-0012){ref-type="ref"}; Prufer et al. [2017](#phy213959-bib-0045){ref-type="ref"}). Opportunities abound to use the data in ExAC, GTEx, and other large‐scale population‐based repositories such as the British Biobank (Khera et al. [2018](#phy213959-bib-0025){ref-type="ref"}; Yengo et al. [2018](#phy213959-bib-0065){ref-type="ref"}) as the springboard toward developing novel and medically important research questions with high biological and biomedical significance.
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